XML 48 R35.htm IDEA: XBRL DOCUMENT v3.26.1
Fair Value Disclosures (Tables)
3 Months Ended
Feb. 28, 2026
Fair Value Disclosures [Abstract]  
Schedule of Financial Assets and Liabilities Accounted for at Fair Value on Recurring Basis
February 28, 2026 (1)
$ in thousands
Level 1
Level 2
Level 3
Counterparty
and Cash
Collateral
Netting (2)
Total
Assets:
Financial instruments owned:
Corporate equity securities ..................................................................................
$7,339,191
$354,960
$218,483
$
$7,912,634
Corporate debt securities .....................................................................................
5,401,094
50,755
5,451,849
Collateralized debt obligations and collateralized loan obligations ...............
591,727
61,455
653,182
U.S. government and federal agency securities ................................................
2,524,173
67,934
2,592,107
Municipal securities ..............................................................................................
556,120
556,120
Sovereign obligations ............................................................................................
928,270
1,038,133
1,966,403
Residential mortgage-backed securities ............................................................
2,123,844
6,134
2,129,978
Commercial mortgage-backed securities ..........................................................
2,150
355
2,505
Other asset-backed securities .............................................................................
630,244
244,714
874,958
Loans and other receivables ................................................................................
2,156,054
85,396
2,241,450
Derivatives ..............................................................................................................
155
7,079,249
14,691
(5,186,913)
1,907,182
Investments at fair value ......................................................................................
13,569
167,195
180,764
Total financial instruments owned, excluding Investments at fair value
based on NAV ....................................................................................................
$10,791,789
$20,015,078
$849,178
$(5,186,913)
$26,469,132
Securities received as collateral ..........................................................................
$393,867
$
$
$
$393,867
Liabilities:
Financial instruments sold, not yet purchased:
Corporate equity securities ..................................................................................
$6,457,960
$119,236
$167
$
$6,577,363
Corporate debt securities .....................................................................................
3,196,057
555
3,196,612
Collateralized debt obligations and collateralized loan obligations ...............
1,000
1,000
U.S. government and federal agency securities ................................................
1,590,146
16
1,590,162
Municipal securities ..............................................................................................
88
88
Sovereign obligations ............................................................................................
688,027
837,099
1,525,126
Residential mortgage-backed securities ............................................................
2,041
2,041
Loans .......................................................................................................................
264,838
921
265,759
Derivatives ..............................................................................................................
56
6,858,114
43,253
(5,600,436)
1,300,987
Total financial instruments sold, not yet purchased .......................................
$8,736,189
$11,278,489
$44,896
$(5,600,436)
$14,459,138
Other secured financings ......................................................................................
$
$412,338
$11,685
$
$424,023
Obligation to return securities received as collateral .......................................
393,867
393,867
Long-term debt .......................................................................................................
2,662,691
1,024,067
3,686,758
(1)Excludes investments at fair value based on net asset value (“NAV”) of $1.61 billion at February 28, 2026 by level within the fair value hierarchy.
(2)Represents counterparty and cash collateral netting across the levels of the fair value hierarchy for positions with the same counterparty.
November 30, 2025 (1)
$ in thousands
Level 1
Level 2
Level 3
Counterparty
and Cash
Collateral
Netting (2)
Total
Assets:
Financial instruments owned:
Corporate equity securities ..................................................................................
$7,664,824
$249,847
$218,853
$
$8,133,524
Corporate debt securities .....................................................................................
5,367,201
37,578
5,404,779
Collateralized debt obligations and collateralized loan obligations ...............
645,798
40,187
685,985
U.S. government and federal agency securities ................................................
2,342,718
106,633
2,449,351
Municipal securities ..............................................................................................
563,994
563,994
Sovereign obligations ............................................................................................
860,832
815,722
1,676,554
Residential mortgage-backed securities ............................................................
1,827,092
6,663
1,833,755
Commercial mortgage-backed securities ..........................................................
10,458
348
10,806
Other asset-backed securities .............................................................................
909,474
133,001
1,042,475
Loans and other receivables ................................................................................
2,111,517
127,720
2,239,237
Derivatives ..............................................................................................................
72
5,519,463
10,311
(3,705,764)
1,824,082
Investments at fair value ......................................................................................
13,567
163,107
176,674
Total financial instruments owned, excluding Investments at fair value
based on NAV ....................................................................................................
$10,868,446
$18,140,766
$737,768
$(3,705,764)
$26,041,216
Securities received as collateral ..........................................................................
$200,495
$
$
$
$200,495
Liabilities:
Financial instruments sold, not yet purchased:
Corporate equity securities ..................................................................................
$5,571,534
$47,631
$155
$
$5,619,320
Corporate debt securities .....................................................................................
2,761,794
3,720
2,765,514
Collateralized debt obligations and collateralized loan obligations ...............
627
627
U.S. government and federal agency securities ................................................
1,913,403
4
1,913,407
Sovereign obligations ............................................................................................
796,564
540,555
1,337,119
Loans .......................................................................................................................
184,391
9,757
194,148
Derivatives ..............................................................................................................
24
5,429,227
45,953
(3,985,187)
1,490,017
Total financial instruments sold, not yet purchased .......................................
$8,281,525
$8,964,229
$59,585
$(3,985,187)
$13,320,152
Other secured financings ......................................................................................
$
$412,510
$13,454
$
$425,964
Obligation to return securities received as collateral ......................................
200,495
200,495
Long-term debt .......................................................................................................
2,671,485
1,063,358
3,734,843
(1)Excludes investments at fair value based on NAV of $1.68 billion at November 30, 2025 by level within the fair value hierarchy.
(2)Represents counterparty and cash collateral netting across the levels of the fair value hierarchy for positions with the same counterparty.
Schedule of Investments Measured at Fair Value Based on Net Asset Value Per Share Information about our investments in entities that have the
characteristics of an investment company:
February 28, 2026
$ in thousands
Fair Value
(1)
Unfunded
Commitments
Redemption
Frequency
Redemption
Notice Period
Hedge
Funds (2) ..............
$781,873
$
Quarterly (41%)
Monthly (39%)
N/R (20%)
45 - 90 days
45 - 60 days
N/R
Private Equity
Funds (3) ..............
69,295
23,473
N/R (100%)
N/R
Credit
Funds (4) ..............
497,569
23,847
Quarterly (53%)
Monthly (2%)
N/R (45%)
90 days
30 days
N/R
Real Estate and
Other Funds (5) ....
261,589
111,269
Quarterly (12%)
N/R (88%)
90 days
N/R
Total ......................
$1,610,326
$158,589
November 30, 2025
$ in thousands
Fair Value
(1)
Unfunded
Commitments
Redemption
Frequency
Redemption
Notice Period
Hedge
Funds (2) ............
$888,880
$
Quarterly (42%)
Monthly (41%)
N/R (17%)
45 - 90 days
45 - 60 days
N/R
Private Equity
Funds (3) ............
66,476
26,828
N/R (100%)
N/R
Credit Funds (4)
490,321
23,847
Quarterly (56%)
Monthly (2%)
N/R (42%)
90 days
30 days
N/R
Real Estate and
Other Funds (5) .
235,846
114,872
Quarterly (19%)
N/R (81%)
90 days
N/R
Total ...................
$1,681,523
$165,547
N/R - Not redeemable
(1)Where fair value is calculated based on NAV, fair value has been derived from
each of the funds’ capital statements.
(2)Includes investments in hedge funds that invest, long and short, primarily in
both public and private equity securities in domestic and international
markets, commodities and multi-asset securities.
(3)Includes investments in equity funds that invest in the equity of various U.S.
and foreign private companies in a broad range of industries. These
investments cannot be redeemed; instead, distributions are received through
the liquidation of the underlying assets of the funds which are primarily
expected to be liquidated in approximately one to nine years.
(4)Primarily includes investments in funds that invest in:
Distressed and special situations long/short credit strategies across
sectors and asset types;
Short-term trade receivables and payables that are expected to generally be
outstanding between 90 to 120 days; and
Distressed and event-driven opportunities across structured credit,
opportunistic credit, and private credit.
(5)Primarily includes investments in corporate real estate strategies focused on
buying or building real estate businesses and investments in venture capital
funds.
Schedule of Fair Value Assets and Liabilities Measured on Recurring Basis Unobservable Input Reconciliation
For instruments still held at
February 28, 2026, changes
in unrealized gains/(losses)
included in:
$ in thousands
Balance at
November 30,
2025
Total gains/
losses
(realized
and
unrealized)
(1)
Purchases
Sales
Settlements
Issuances
Net
transfers
into/
(out of)
Level 3
Balance at
February 28,
2026
Earnings (1)
Other
comprehensive
income (1)
Assets:
Financial instruments
owned:
Corporate equity securities ...
$218,853
$(6,089)
$12,452
$(3,342)
$(397)
$
$(2,994)
$218,483
$(6,456)
$
Corporate debt securities ......
37,578
1,716
66,717
(66,617)
(629)
11,990
50,755
(579)
CDOs and CLOs .......................
40,187
(7,026)
39,519
(11,654)
429
61,455
(5,505)
RMBS ........................................
6,663
(127)
(402)
6,134
(127)
CMBS ........................................
348
7
355
7
Other ABS .................................
133,001
(45,135)
119,288
(7,909)
(2,919)
48,388
244,714
(45,257)
Loans and other receivables .
127,720
(973)
214,243
(207,158)
(790)
(47,646)
85,396
2,488
Investments at fair value .......
163,107
4,636
250
(23)
(775)
167,195
3,895
Liabilities:
Financial instruments sold,
not yet purchased:
Corporate equity securities ...
$155
$12
$
$
$
$
$
$167
$(12)
$
Corporate debt securities ......
3,720
192
(3,357)
555
(192)
CDOs and CLOs .......................
3
(3)
Loans ........................................
9,757
(40)
(697)
725
(8,824)
921
(1,687)
Net derivatives (2) ...................
35,642
(11,191)
(5,332)
1,484
7,638
321
28,562
7,430
Other secured financings .......
13,454
(144)
120
(1,745)
11,685
134
Long-term debt ........................
1,063,358
(18,984)
(23,695)
6,737
(3,349)
1,024,067
(34,884)
53,868
(1)Realized and unrealized gains/losses are primarily reported in Principal transactions revenues. Changes in instrument-specific credit risk related to structured notes
within Long-term debt are presented net of tax in our Consolidated Statements of Comprehensive Income.
(2)Net derivatives represent Financial instruments owned—Derivatives and Financial instruments sold, not yet purchased —Derivatives.
For instruments still held at
February 28, 2025, changes in
unrealized gains/(losses)
included in:
$ in thousands
Balance at
November 30,
2024
Total gains/
losses
(realized
and
unrealized)
(1)
Purchases
Sales
Settlements
Issuances
Net
transfers
into/
(out of)
Level 3
Balance at
February 28,
2025
Earnings (1)
Other
comprehensive
income (1)
Assets:
Financial instruments
owned:
Corporate equity
securities .......................
$239,364
$2,864
$1,703
$(1,016)
$
$
$(30,506)
$212,409
$5,300
$
Corporate debt securities
24,931
(1,002)
6,753
(895)
(3,862)
25,925
(1,248)
CDOs and CLOs .................
63,976
(4,646)
17,177
(9,981)
5,301
71,827
(4,664)
Sovereign obligations .......
172
2
(174)
(1)
RMBS ..................................
7,714
(167)
(21)
7,526
(59)
CMBS ..................................
477
(6)
471
Other ABS ...........................
103,214
(1,889)
54,165
(4,709)
(2,312)
(1,150)
147,319
(1,318)
Loans and other
receivables ....................
152,586
(949)
78,763
(53,590)
(9,170)
(13,876)
153,764
(1,545)
Investments at fair value .
137,865
393
21,288
(1,665)
157,881
393
Liabilities:
Financial instruments
sold, not yet
purchased:
Corporate equity
securities .......................
$208
$(72)
$
$454
$
$
$
$590
$72
$
Corporate debt securities
165
(40)
(383)
1,025
346
1,113
24
RMBs ..................................
15
15
CMBS ..................................
1,153
1
35
(35)
1,154
(1)
Loans ..................................
16,864
301
(1,917)
75
(14,475)
848
89
Net derivatives (2) .............
22,286
(16,020)
22,588
(279)
299
13,202
42,076
14,559
Other secured financings .
14,884
(1,938)
(241)
12,705
1,938
Long-term debt ..................
821,903
(55,177)
124,554
(30,596)
860,684
29,428
25,749
(1)Realized and unrealized gains/losses are primarily reported in Principal transactions revenues. Changes in instrument-specific credit risk related to structured notes
within Long-term debt are presented net of tax in our Consolidated Statements of Comprehensive Income.
(2)Net derivatives represent Financial instruments owned—Derivatives and Financial instruments sold, not yet purchased—Derivatives.
Schedule of Fair Value Inputs Assets and Liabilities Quantitative Information Table
February 28, 2026
Financial Instruments Owned
Fair Value
(in
thousands)
Valuation
Technique
Significant Unobservable Input(s)
Input / Range
Weighted
Average
Corporate equity securities .....................
$218,483
Non-exchange-traded securities
Market approach
Price
$0
-
$1,115
$90
Volatility
benchmarking
Volatility
45%
-
49%
48%
Corporate debt securities ........................
$50,755
Market approach
Price
$58
-
$122
$92
Discounted cash
flows
Discount rate/yield
22%
-
26%
24%
CDOs and CLOs ..........................................
$31,965
Discounted cash
flows
Constant prepayment rate
15%
-
20%
16%
Constant default rate
2%
Loss severity
30%
Discount rate/yield
13%
-
15%
14%
Market approach
Price
$98
-
$118
$101
RMBS ...........................................................
$6,134
Discounted cash
flows
Constant prepayment rate
10%
Constant default rate
0.5%
Loss severity
45%
Discount rate/yield
20%
Other ABS ...................................................
$242,697
Discounted cash
flows
Discount rate/yield
10.9%
-
15.8%
15.2%
Cumulative loss rate
10.5%
-
17.4%
16.5%
Duration (years)
1.1
-
1.5
1.2
Market approach
Price
$118
-
$135
$132
Scenario analysis
Estimated recovery percentage
64%
-
69%
68%
Loans and other receivables ...................
$85,396
Market approach
Price
$8
-
$118
$106
Scenario analysis
Estimated recovery percentage
18%
-
222%
92%
Derivatives ..................................................
$11,104
Embedded options
Market approach
Basis points upfront
0.3
-
0.5
0.4
Equity options
Volatility
benchmarking
Volatility
51%
Investments at fair value ..........................
$161,250
Private equity securities
Market approach
Price
$0
-
$27,989
$2,838
Discount rate/yield
28%
Estimated revenue
$29,760,909
Financial Instruments Sold, Not Yet Purchased:
Derivatives ..................................................
$43,253
Equity options
Volatility
benchmarking
Volatility
39%
-
67%
53%
Embedded options
Market approach
Basis points upfront
7.2
-
19.9
12.8
Other secured financings .........................
$11,685
Scenario analysis
Estimated recovery percentage
74%
-
100%
95%
Market approach
Price
$117
-
$118
$118
Long-term debt ..........................................
$1,024,067
Structured notes
Market approach
Price
$70
-
$120
$100
November 30, 2025
Financial Instruments Owned
Fair Value
(in
thousands)
Valuation
Technique
Significant Unobservable Input(s)
Input / Range
Weighted
Average
Corporate equity securities .....................
$218,853
Non-exchange-traded securities
Market approach
Price
$0
-
$486
$85
Volatility
benchmarking
Volatility
44%
-
48%
47%
Corporate debt securities ........................
$37,578
Market approach
Price
$49
-
$121
$72
Discounted cash
flows
Discount rate/yield
18%
-
20%
19%
Scenario analysis
Estimated recovery percentage
30%
CDOs and CLOs ..........................................
$25,824
Discounted cash
flows
Constant prepayment rate
20%
Constant default rate
2%
Loss severity
30%
Discount rate/yield
17%
Market approach
Price
$98
-
$100
$99
RMBS ...........................................................
$6,663
Discounted cash
flows
Constant prepayment rate
12%
Constant default rate
0.3%
Loss severity
20%
Discount rate/yield
15%
Other ABS ...................................................
$129,693
Discounted cash
flows
Discount rate/yield
15.5%
-
15.7%
15.6%
Cumulative loss rate
16.0%
-
16.4%
16.2%
Duration (years)
1.1
-
1.2
1.1
Market approach
Price
$116
-
$133
$130
Scenario analysis
Estimated recovery percentage
66%
Loans and other receivables ...................
$127,720
Market approach
Price
$67
-
$129
$97
Scenario analysis
Estimated recovery percentage
8%
-
100%
35%
Derivatives ..................................................
$6,094
Embedded options
Market approach
Basis points upfront
0.4
-
0.5
0.5
Equity options
Volatility
benchmarking
Volatility
34%
Investments at fair value ..........................
$157,162
Private equity securities
Market approach
Price
$0
-
$27,989
$2,722
Discount rate/yield
28%
Estimated revenue
$29,818,082
Financial Instruments Sold, Not Yet Purchased:
Corporate debt securities ........................
$3,720
Scenario analysis
Estimated recovery percentage
30%
Loans ...........................................................
$9,757
Market approach
Price
$100
-
$129
$117
Scenario analysis
Estimated recovery percentage
30%
Derivatives ..................................................
$45,953
Equity options
Volatility
benchmarking
Volatility
34%
-
61%
58%
Embedded options
Market approach
Basis points upfront
0.0
-
21.0
13.3
Other secured financings .........................
$13,454
Scenario analysis
Estimated recovery percentage
74%
-
100%
96%
Market approach
Price
$114
-
$117
$115
Long-term debt ..........................................
$1,063,358
Structured notes
Market approach
Price
$72
-
$120
$101
Schedule of Fair Value Option Gains (Losses) and Summary of Contractual Principal Exceeds Fair Value for Loans and Other Receivables Fair value option gains (losses):
Three Months Ended
 February 28,
$ in thousands
2026
2025
Financial instruments owned:
Loans and other receivables (1) .............................................
$(28,722)
$13,283
Other secured financings:
Other changes in fair value (1) ................................................
$(309)
$1,938
Long-term debt:
Changes in instrument-specific credit risk (2) ......................
$77,896
$37,898
Other changes in fair value (1) ................................................
(58,916)
16,944
(1)Other changes in fair value are included in Principal transactions revenues.
(2)Changes in fair value of structured notes related to instrument-specific credit
risk are presented net of tax in our Consolidated Statements of
Comprehensive Income.
Difference between contractual principal and fair value (1):
$ in thousands
February 28,
 2026
November 30,
 2025
Financial instruments owned:
Loans and other receivables (2) ................................
$2,219,310
$2,378,747
Loans and other receivables on nonaccrual
status and/or 90 days or greater past due (2) .....
420,878
319,394
Loans and other receivables 90 days or
greater past due (2) ..............................................
70,748
100,300
Long-term debt ............................................................
222,020
166,273
Other secured financings ...........................................
(4,798)
237
(1)Amounts indicate contractual principal greater than or (less than) fair value.
(2)Interest income is recognized separately from other changes in fair value and
is included in Interest revenues.
Fair value of loans and other receivables on nonaccrual status:
$ in thousands
February 28,
 2026
November 30,
 2025
Financial instruments owned:
Loans and other receivables on nonaccrual status
and/or 90 days or greater past due ...........................
$109,143
$119,900
Loans and other receivables 90 days or greater
past due .....................................................................
66,657
47,000